50681-25-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50681-25-9,4-Pyridazinecarboxylic Acid,as a common compound, the synthetic route is as follows.
Example 47-1 : Synthesis of (2R,4S)-5-Biphenyl-4-yl-2-methyl-4-[(pyridazine-4- carbonyl)-amino]-pentanoic acid; To a stirred solution of pyridazine-4-carboxylic acid (21 mg, 0.17 mmol) in DMF (6 ml_) is added HOBT (26 mg, 0.17 mmol) and HBTU (65 mg, 0.17 mmol) and the mixture is stirred at room temperature for 10 minutes. (2R,4S)-4-Amino-5-biphenyl-4-yl-2-methyl-pentanoic acid ethyl ester hydrochloride (50 mg, 0.14 mmol) and DIEA (42 mg, 0.56 mmol) are added. After stirring the mixture at room temperature for 18 hours, water is added and the mixture is extracted three times with ethyl acetate. The combined organic layers are washed with water and brine then is dried over magnesium sulfate. The solvent is removed under reduced pressure to give the title compound; HPLC retention time 1.19 minutes (condition C); MS 390.3 (M+H); 1 H NMR (400 MHz, DMSO-d6): ? ppm 1 .08-1 .10 (d, J=7.07 Hz, 3H), 1 .59-1 .66 (m, 1 H), 1 .88-1 .95 (m, 1 H), 2.46-2.53 (m, 1 H), 2.85-2.87 (d, J=6.82 Hz, 2H), 4.22- 4.30 (m, 1 H), 7.29-7.32 (m, 2H), 7.33-7.36 (m, 1 H), 7.42-7.46 (m, 2H), 7.57-7.59 (m, 2H), 7.62-7.65 (m, 2H), 7.91 -7.93 (q, J=2.27 Hz, 1 H), 8.76-8.78 (d, J=8.59 Hz, 1 H), 9.41 -9.43 (m, 1 H), 9.45-9.46 (m, 1 H), 12.09 (s, 1 H).
As the paragraph descriping shows that 50681-25-9 is playing an increasingly important role.
Reference£º
Patent; NOVARTIS AG; COPPOLA, Gary Mark; IWAKI, Yuki; KARKI, Rajeshri Ganesh; KAWANAMI, Toshio; KSANDER, Gary Michael; MOGI, Muneto; SUN, Robert; WO2010/136474; (2010); A2;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem